CYTOMX THERAPEUTICS INC (CTMX)

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.

Let's have a look at the gap up and gap down stocks in today's session.

Monday's after hours session: top gainers and losers

Let's have a look at what is happening on the US markets after the closing bell on Monday. Below you can find the top gainers and losers in today's after hours session.

CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally...

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

- Phase 1a dose escalation for CX-904 (EGFR-CD3 PROBODY® T-cell engager) continues to advance. Potential Phase 1b initiation in 2025. - - Phase 1 study of...

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally...

CytomX Therapeutics to Present at Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally...

CTMX Stock Earnings: CytomX Therapeutics Beats EPS, Beats Revenue for Q2 2024

CTMX stock results show that CytomX Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

- CX-904 (EGFR-CD3 PROBODY® T-cell engager) Phase 1a enrollment continues, primarily focused in PDAC, NSCLC, and HNSCC. Program update expected by the end...

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally...

CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally...

Buy Alert: 3 Penny Stocks That Will Explode in 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips When the term penny stocks to buy is thrown around, ideas of high-risk-high-rew...

Buy Alert: 3 Penny Stocks That Will Explode in 2024

Investors should consider these three penny stocks to buy before their success makes them more expensive to gain from.

Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates

/PRNewswire/ -- USA News Group – Recognized as one of the most lethal cancers, researchers are striving to improve survival rates for pancreatic cancer...

Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates

/CNW/ -- USA News Group – Recognized as one of the most lethal cancers, researchers are striving to improve survival rates for pancreatic cancer patients by...

No Memes, Ma’am! Try a Sensible Biotech Bet With CytomX Therapeutics Stock.

It's time to take CytomX Therapeutics stock seriously as CytomX Therapeutics forges a crucial partnership with a pharmaceutical powerhouse.

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally...

CytomX Therapeutics Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally...

Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection

/PRNewswire/ -- USA News Group – Hope is rising in the fight against one of the deadliest cancers in the world, as a new study recently claimed that a blood...

Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection

/CNW/ -- USA News Group – Hope is rising in the fight against one of the deadliest cancers in the world, as a new study recently claimed that a blood test can...

SOUN Stock Alert: SoundHound AI Announces New Partnership With Perplexity

SoundHound AI stock is slipping on Thursday as SOUN investors appear unimpressed by a new LLM collaboration with Perplexity.

Dear NVDA Stock Fans, Mark Your Calendars for June 2

Nvidia stock fans will want to keep an eye on the tech company when June 2 rolls around for a potential catalyst for NVDA shares.

Why Is CytomX (CTMX) Stock Down 43% Today?

CytomX Therapeutics stock is falling hard on Thursday after the company posted lackluster results in a cancer treatment clinical trial update.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Pre-market stock movers are a hot topic this morning and we've got traders covered with all of the news behind these movements on Thursday!

CTMX Stock Earnings: CytomX Therapeutics Beats EPS, Beats Revenue for Q1 2024

CTMX stock results show that CytomX Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

CTMX Stock Earnings: CytomX Therapeutics Beats EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips CytomX Therapeutics (NASDAQ:CTMX) just reported results for the first quarter o...

CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

- Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors - - First dose cohort...

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

- CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1...

CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)

- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform -                   - Phase 1...

Breaking on The Street Stocks To Watch Now! CTMX, PRSO, IMCC, KAVL, VTAK

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Pre-market stock movers are worth checking out with our coverage of all the latest and greatest news happening on Thursday!